Discover ioCells^™

Programmed identity
in every cell

Mature, functional human
iPSC-derived cells within days,
powered by opti-ox™

The future of human health will be defined by technologies that accelerate the world's access to more effective medicines.

Human cells are a cornerstone of fundamental disease research, drug discovery, and clinical translation. Yet, despite decades of research into iPSCs, emerging cures for some of the world’s most pervasive diseases have been bottlenecked by a lack of access to standardised, easy to use and readily accessible human cells.

We built ioCells to solve this challenge.

Developed on our platform, and powered by opti-ox technology, ioCells are human cells precision reprogrammed from iPSCs consistently, at scale. With ioCells, scientists no longer need to battle with variance, unreliability, physiological irrelevance and long experimental timelines. Instead, scientists can finally focus on the next great advances in human health.

ioCells are for research use only.

Browse ioCells portfolio

ioWild Type Cells™

ioWild Type Cells are defined, easy-to-use, functional iPSC-derived human cells from a healthy donor background that are ready for fundamental research and drug discovery experimentation within days.

Explore now

ioDisease Model Cells™

ioDisease Model Cells are ioWild Type Cells engineered to contain disease-relevant mutations. ioDisease Model Cells and ioWild Type Cells form an isogenic pair allowing scientists to make true comparisons.

Explore now

ioCRISPR-Ready Cells™

ioCRISPR-Ready Cells are human iPSC-derived cells constitutively expressing Cas9 nuclease for rapid gene knockout generation. 

Explore now

Custom Cell Development

We provide our partners with the ability to develop and access any human cell type at scale, removing the experimental burden of cell models that are not translatable, scalable or an accurate representation of disease

Explore now

Benchtop benefits

Consistent

Our platform ensures consistency between every batch of cells, overcoming the challenge of data reproducibility.

Cost-effective

ioCells generate quality data at industry leading seeding densities. You can do more with every vial as every well saves you money.

Defined

Every ioCell has its identity characterised by ICC, RT-qPCR and RNA-Seq at minimum.

Easy-to-use

ioCells are delivered cryopreserved and require a simple protocol using an open-source medium to get started.

Quick

Precision reprogrammed cells mature rapidly, meaning cells are ready for experimentation and data gathering within days post-revival.

Scalable

With opti-ox technology we can make billions of consistently reprogrammed cells, surpassing the demands of industrial workflows.

Our precision cellular reprogramming technology

 

Every ioCell is powered by opti-ox.

Using opti-ox, populations of stem cells are precisely and consistently reprogrammed into a chosen cell identity. Each vial of ioCells contains a defined and highly characterised population of iPSC-derived human cells that are ready for quality data production in a matter of days. Their high lot-to-lot consistency provides a reliable cell model that enables scientists to conduct repeatable and scalable experiments in drug discovery and disease research. 

Compare opti-ox to other iPSC differentiation methods

Product resources

Poster

Generation and characterisation of a panel of human iPSC-derived neurons and microglia carrying early and late onset relevant mutations for Alzheimer’s disease

Smith et al. 
bit.bio
2024

Downlaod

Webinar

Running Large-Scale CRISPR Screens in Human Neurons

Emmanouil Metzakopian | Vice President, Research and Development | bit.bio

Javier Conde-Vancells | Director Product Management | bit.bio

Watch now

Publication

3D bioprinting of iPSC neuron-astrocyte coculture

Whitehouse, et al
JoVE Journal of Visualized Experiments 
2023

Using ioGlutamatergic Neurons

Read more

Webinar

Addressing the Reproducibility Crisis | Driving Genome-Wide Consistency in Cellular Reprogramming

Dr Ania Wilczynska | Head of Computational Genomics | Non-Clinical | bit.bio

Watch now

Talk

Industrialising Cellular Reprogramming: Leveraging opti-ox™ Technology to Manufacture Human Cells with Unprecedented Consistency

Innovation showcase talk at ISSCR

Marius Wernig MD, PhD | Stanford 

Mark Kotter, MD, PhD | bit.bio

Watch now

Poster

Modelling neurodegeneration: Human isogenic system to study FTD & ALS

Oosterveen, et al

bit.bio & Charles River Laboratories

2023

Download

Webinar

Rethinking Developmental Biology With Cellular Reprogramming

Mark Kotter | CEO and founder | bit.bio

Marius Wernig | Professor Departments of Pathology and Chemical and Systems Biology |  Stanford University

Watch now

Talk

Precision Cellular Reprogramming for Scalable and Consistent Human Neurodegenerative Disease Models

Madeleine Garrett | Field Application Specialist | bit.bio

Watch now

Poster

Development and characterisation of a robust in vitro disease model to study tauopathies

Ritsma et al

Charles River Laboratories & bit.bio

2022

Download

Poster

Validation of ALS-relevant phenotypes in precision reprogrammed iPSC-derived glutamatergic Neurons containing a TDP-43 M337V mutation.

Ritsma, et al

Charles River Laboratories & bit.bio

2022

Download

Poster

Rapid and consistent generation of functional microglia from reprogrammed hiPSCs to study neurodegeneration and neuroinflammation

Raman, et al

bit.bio

2022

Download

Publication

Interferon-γ exposure of human iPSC-derived neurons alters major histocompatibility complex I and synapsin protein expression | Publication

Pavinlek, et al

Frontiers in Psychiatry

2022

 

Using ioGlutamatergic Neurons

 

 

Read more

Publication

Glutamatergic Neurons and Brain Cyst Formation | Publication

Bando, et al

Frontiers in Cellular and Infection Microbiology

2022

 

Using ioGlutamatergic Neurons

 

 

Read more

Publication

Compounds co-targeting kinases in axon regulatory pathways promote regeneration and behavioral recovery after spinal cord injury in mice | Publication

Mah, et al

Experimental Neurology

2022

 

Using ioGlutamatergic Neurons

Read more

Webinar

Modelling neurodevelopment | Investigating the impact of maternal immune activation on neurodevelopment using human iPSC-derived cells

Dr Deepak Srivastava | King’s College London

Watch now

Video

Partnering with Charles River to advance CNS drug discovery with ioGlutamatergic Neurons™

Dr Marijn Vlaming | Head of Biology, et al.

Charles River & bit.bio

Watch now

Video

In Conversation with Charles River

Dr Marijn Vlaming | Head of Biology
Charles River

Watch now

Talk

CRISPR and the Art of Perturbation Screening: Unbiased functional genomic screening meets the best human cellular models

Kam Dhaliwal | SVP Strategic Alliances | bit.bio

Talk at ELRIG CRISPR in Drug Discovery

Watch now

Poster

High Content Analysis of 2D and 3D cellular models for target and phenotypic drug discovery

Lachize, et al

Courtesy of Charles River Laboratories

2020

Download

Talk

Consistent and scalable human iPSC-derived cells for in vitro disease modelling and drug discovery

Kam Dhaliwal |  SVP Strategic Alliances | bit.bio
Dr Thomas Moreau | Head of Research | bit.bio

Talk at ELRIG Drug Discovery Digital

Watch now

Related pages

Resources Explore our latest scientific insights, webinars, blogs and videos

Our platform Discover the cell identity coding platform that powers our ioCells

News Read our latest updates and press coverage